Product Information
Registration Status: ActiveSIN09657P
HYPERRAB S/D INJECTION is approved to be sold in Singapore with effective from 1998-02-26. It is marketed by GRIFOLS ASIA PACIFIC PTE LTD, with the registration number of SIN09657P.
This product contains Rabies Immune Globulin (Human) 150 iu/ml in the form of INJECTION. It is approved for INTRAMUSCULAR use.
This product is manufactured by Grifols Therapeutics Inc. in UNITED STATES.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
IMOGAM Rabies Pasteurized is indicated for post-exposure prophylaxis in persons suspected of exposure to rabies, who have not previously received a complete immunization regimen with a cell culture produced rabies vaccine. Persons previously vaccinated with other types of rabies vaccines in whom adequate antibody levels have not been demonstrated should receive full post-exposure prophylaxis with RIG and a cell culture-produced rabies vaccine. IMOGAM Rabies Pasteurized should be administered promptly after exposure, in conjunction with rabies vaccine. If IMOGAM Rabies Pasteurized is not administered as recommended at the initiation of the post-exposure rabies vaccine series, it can be administered up to eight days following the first dose of the rabies vaccine. Since rabies vaccine-induced antibody begins to appear within one week, there is no value in administering rabies immune globulin more than eight days after rabies vaccination has begun. Recommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the National Advisory Committee on Immunization (NACI), the Advisory Committee on Immunization Practices (ACIP), and the World Health Organization (WHO).
Indication
For use in prophylaxis against rabies virus in patients who have been exposed to the virus and are immunocompromised or have not previously recieved the rabies vaccine [FDA Label].
Mechanism of Action
Rabies immune globulin binds the rabies virus, preventing it from invading the central nervous system [FDA Label]. This affords time for the rabies vaccine, which is also administered in cases of rabies exposure, to induce an immune response to destroy the virus. Rabies immunoglobulin should only be administered up to eight days after exposure as the host begins to produce sufficient antibodies to the virus one week after exposure. Repeat dosing should also be avoided as it may interfere with induction of immune response by the rabies vaccine.
Toxicity
No toxicological studies have been performed. Isolated cases of angioneurotic edema, skin rash, nephrotic syndrome, and anaphylactic shock after injection have been noted [FDA Label].
Active Ingredient/Synonyms
Rabies immune globulin | Rabies immune globulin (human) | Rabies immune globulin human | Rabies immune globulin, human | Rabies immune globulin,human | Rabies immunoglobulins | Human rabies virus immune globulin |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.